News and Events

a group of killer T cells (light blue) surround a cancer cell (dark red/black)

Computational model finds signatures of T cell resilience in solid tumors

Evaluating T cell resilience can help researchers predict — and possibly improve — immunotherapy outcomes.

Clinical trial researching therapy for some small cell lung cancers

Anish Thomas, M.B.B.S., M.D., Lasker Clinical Research Scholar in the Developmental Therapeutics Branch, is leading NCI’s participation in a trial researching therapies for small cell lung cancer.

Kandice Tanner receives Arthur S. Flemming Award

Kandice Tanner, Ph.D., a Senior Investigator in the Laboratory of Cell Biology, is a recipient of the 2021 Arthur S. Flemming Awards, which honor the accomplishments of midcareer federal employees. Dr. Tanner received the award for her breakthrough discovery that patterns of cancer spread in humans can be recreated in zebrafish. This novel animal model allows researchers to address organ-specific drug responses and develop effective immunotherapies in a preclinical platform.

Clinical trial researches therapy for VEXAS syndrome

A clinical trial led by Dennis Hickstein, M.D., Senior Investigator in the Immune Deficiency Cellular Therapy Program, is researching a therapy for people with VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) syndrome.

Protein signature in the blood linked to prostate cancer lethality in men of African ancestry

African American men have an increased risk for lethal prostate cancer. CCR researchers have found that an immunity-related protein signature in the blood is more prevalent in men of African ancestry, which may help explain this devastating health disparity.

Clinical trial researches three-part immunotherapy regimen for gastric or head and neck cancer

Jason M. Redman, M.D., Assistant Research Physician in the Genitourinary Malignancies Branch, is leading a study researching a three-part immunotherapy regimen in adults with gastric or head and neck cancer.

CCR scientists to present at 2022 AACR Annual Meeting in New Orleans

The American Association for Cancer Research (AACR) Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. Several CCR scientists will present their research at the AACR Annual Meeting.

A series of images depicting computed tomography (CT) scans of prostate cancer.

Clinical trial aims to reduce hormone therapy side effects for people with prostate cancer

A team at CCR is investigating a new device to deliver hormone therapy directly into prostate cancer tumors. The approach could improve patient quality of life by reducing burdensome side effects of current hormone therapies.

New Milestones publication now available

Every year, CCR makes remarkable contributions to the understanding, detection, treatment and prevention of cancer. This issue of our annual publication, Milestones, features 14 of our top scientific advances from the past year. These discoveries include basic research to understand cancer cells, promising advances in immunotherapy for solid tumors, precision oncology for selecting the best treatment for a patient and new insights into the role of the tumor microenvironment and the microbiota in cancer treatment. Other major advances include new technology development achieved through interdisciplinary teamwork, health disparities research relating to prostate cancer and studies that led to several Food and Drug Administration approvals.

First-in-human clinical trial evaluates drug for pancreatic cancer and other solid tumors

Christine Alewine, M.D., Ph.D., a Lasker Clinical Research Scholar in the Laboratory of Molecular Biology, is leading CCR participation in a first-in-human trial to evaluate a drug for therapy of pancreatic cancer and other solid tumors. The drug aims to attack a physical barrier that helps to hide the tumor from the body’s immune system.

Breadcrumb